Dec. 25 at 5:43 PM
$ONCY Small-molecule inhibitors od the RAS,/MAPK pathway (such as BRAF and MEK inhibitors like IMRX's atebimetnib) often produce systemic toxicites because the targeted pathways are essential for the regulation and maintenance of normal healthy cells.
Pan-RAS(ON) inhibitors, like RVMD's daraxonrasib, have a high rate of low-ti-moderate toxicities that necessitates frequent and significant dose adjustments. Approximately 27-41% of patients require dise interruptions or reductions to manage side effects like rash, diarrhea, and stomatitis.
In contrast pelareorep is generally considered a "de-risked" immunotherapy with a safety profile that is more favorable than oral small molecules because pelareorep's replication is restricted only to RAS activated transform led cells.
Consequently, pelareorep is used as a 'platform' therapy because it does not add significant cumulative toxicity to chemotherapy or immunotherapy regimens.
